Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma.
Nobutaka NishimuraMakito MiyakeTakuto ShimizuAkira TachibanaNobumichi TanakaKiyohide FujimotoPublished in: IJU case reports (2022)
Pembrolizumab rechallenge is not recommended in the current clinical setting of metastatic urothelial carcinoma, even for patients who showed complete response to the prior pembrolizumab.